Journal
CANCER LETTERS
Volume 525, Issue -, Pages 170-178Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.10.042
Keywords
Enzalutamide resistance; Prostate cancer; Bone microenvironment; TGFBR2; PTH1R
Categories
Funding
- National Cancer Institute [R01CA230744]
- Van Andel Institute [53010A]
Ask authors/readers for more resources
This study is the first to reveal the contribution of the bone microenvironment to enzalutamide resistance and identifies PTH1R as a feasible target to overcome resistance in prostate cancer bone metastases.
Enzalutamide resistance has been observed in approximately 50% of patients with prostate cancer (PCa) bone metastases. Therefore, there is an urgent need to investigate the mechanisms and develop strategies to overcome resistance. We observed enzalutamide resistance in bone lesion development induced by PCa cells in mouse models. We found that the bone microenvironment was indispensable for enzalutamide resistance because enzalutamide significantly inhibited the growth of subcutaneous C4-2B tumors and the proliferation of C4-2B cells isolated from the bone lesions, and the resistance was recapitulated only when C4-2B cells were co-cultured with osteoblasts. In revealing how osteoblasts contribute to enzalutamide resistance, we found that enzalutamide decreased TGFBR2 protein expression in osteoblasts, which was supported by clinical data. This decrease was possibly through PTH1R-mediated endocytosis. We showed that PTH1R blockade rescued enzalutamidemediated decrease in TGFBR2 levels and enzalutamide responses in C4-2B cells that were co-cultured with osteoblasts. This is the first study to reveal the contribution of the bone microenvironment to enzalutamide resistance and identify PTH1R as a feasible target to overcome the resistance in PCa bone metastases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available